Evidence map›Paper›PMID 29367611›Full record

ArticleScientific reports2018

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.

Bo Gao, Yi Lu, Annemieke J M Nieuweboer, Hongmei Xu, Jonathan Beesley, Ingrid Boere, Anne-Joy M de Graan, Peter de Bruijn, Howard Gurney, Catherine J Kennedy and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Using maximum plasma concentration (CCancer chemotherapy and pharmacology · 2024
    Review
  3. Article
  4. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.Methods in molecular biology (Clifton, N.J.) · 2022
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 3 countries.

Bo GaoDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
Yi LuQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Annemieke J M NieuweboerDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Hongmei XuUnaffiliated, Boston, USA.
Jonathan BeesleyQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Ingrid BoereDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Anne-Joy M de GraanDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Peter de BruijnDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Howard GurneyCrown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia.
Catherine J KennedyDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
Yoke-Eng ChiewDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, Australia.
Sharon E JohnattyQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Philip BealeChris O'Brien Lifehouse, Sydney, Australia.
Michelle HarrisonChris O'Brien Lifehouse, Sydney, Australia.
Craig LuccariniCentre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge University, Cambridge, UK.
Don ConroyCentre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge University, Cambridge, UK.
Ron H J MathijssenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Paul R HarnettThe Westmead Institute for Medical Research, Sydney Medical School, The University of Sydney, Sydney, Australia.
Rosemary L BalleineThe Westmead Institute for Medical Research, Sydney Medical School, The University of Sydney, Sydney, Australia.
Georgia Chenevix-TrenchQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Stuart MacgregorQIMR Berghofer Medical Research Institute, Brisbane, Australia.ORCID http://orcid.org/0000-0001-6731-8142
Anna de FazioDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, Australia. anna.defazio@sydney.edu.au.
The University of Sydney · AUErasmus MC Cancer Institute · NLQIMR Berghofer Medical Research Institute · AUChris O’Brien Lifehouse · AUUniversity of Cambridge · GBWestmead Hospital · AU

Funding

Cancer Research UK C8197/A16565
6 · The paper itself

Abstract

Identifying single nucleotide polymorphisms (SNPs) that influence chemotherapy disposition may help to personalize cancer treatment and limit toxicity. Genome-wide approaches are unbiased, compared with candidate gene studies, but usually require large cohorts. As most chemotherapy is given cyclically multiple blood sampling is required to adequately define drug disposition, limiting patient recruitment. We found that carboplatin and paclitaxel disposition are stable phenotypes in ovarian cancer patients and tested a genome-wide association study (GWAS) design to identify SNPs associated with chemotherapy disposition. We found highly significant SNPs in ABCC2, a known carboplatin transporter, associated with carboplatin clearance (asymptotic P = 5.2 × 10

Indexed as

Genome-Wide Association StudyAntineoplastic AgentsATP-Binding Cassette, Sub-Family C ProteinsCarboplatinCarcinoma, Ovarian EpithelialFemaleGenome, HumanHumansMultidrug Resistance-Associated Protein 2PaclitaxelPolymorphism, Single NucleotideABCC2 protein, humanAntineoplastic AgentsATP-Binding Cassette, Sub-Family C ProteinsCarboplatinMultidrug Resistance-Associated Protein 2Paclitaxel

Identifiers

PMID29367611
PMCPMC5784122
OpenAlexW2806348587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.